Biological E, Providence Therapeutics tie up for mRNA vaccine, to run trials in India, seek EUA
Biological E, Providence Therapeutics tie up for mRNA vaccine, to run trials in India, seek EUA June 01, 2021 × Targets 1 billion doses in 2022; Providence to supply 30 million doses from North American capacity Canadian biotechnology company Providence Therapeutics Holdings Inc and the Hyderabad-based Biological E Ltd have signed up for a licensing and collaboration agreement for Providence’s mRNA vaccine, PTX-Covid19-B. Providence will provide the technology transfer for Biological E to manufacture mRNA vaccines in India, with a minimum production capacity of 600 million doses in 2022 ...